Navigation Links
Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/8/2007

- Conference Call and Webcast on November 9 at 8:00 a.m. PST -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today reported financial results for the three and nine months ended September 30, 2007.

"Halozyme's unique capabilities in navigating the complexities of the extracellular matrix provide a number of exciting opportunities to build shareholder value," said Jonathan Lim, MD, Halozyme's President and CEO. "Building on our track record for accelerated development and commercialization and leveraging the franchises of our partners, we continue to pursue these opportunities by executing our Enable, Improve and Innovate programs. The Enable program focuses on making our partners' drugs better by potentially improving administration, extending product lifecycles, and increasing patients' compliance, and includes HYLENEX recombinant (hyaluronidase human injection) and our Enhanze(TM) Technology for drug delivery. In this regard, we are very pleased that we recently broadened our relationship with Baxter to apply our Enhanze Technology to their GAMMAGARD product. We are also excited about developing our own products through the Improve program, which focuses on co-formulations of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs; and the Innovate program, which focuses on developing new molecular entities targeting the extracellular matrix with some exciting projects underway in oncology and dermatology."

Third Quarter 2007 Highlights

-- The completion of a new agreement with Baxter International Inc. to

a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The ability ... a culture that will allow individuals to perform at ... increasingly important for employers looking to compete in this ... are embracing this trend, as the sector increasingly focuses ... a company, which will have real results on the ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... 2008 Diffusion,Pharmaceuticals LLC, a clinical-stage drug-development ... action that enhances,oxygen diffusion, today announced that ... entitled "Bipolar Trans Carotenoid Salts and Their ... of first-in-class new chemical entities,known as trans ...
... Mass., April 8, 2008 Caliper Life,Sciences, Inc. (Nasdaq: ... Meeting,of Stockholders will be held on June 3, 2008, ... 68 Elm Street, Hopkinton, Massachusetts. The record,date for Caliper ... 16,2008., About Caliper Life Sciences, Caliper Life ...
... pain reliever lands its first national retail drug ... ... ALCiS Health, Inc., a,provider of patented pain relief products, today announced ... cream, ALCiS Daily Relief, at all of its 6,237 stores.,Its introduction onto ...
Cached Biology Technology:Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules 2ALCiS(R) Daily Relief Now Available at Walgreens 2
(Date:9/1/2014)... An increasing amount of research shows an association between ... sedentary lifestyle. Now, a new Cornell University study points ... programs might lead people to eat twice as much ... an action movie while snacking your mouth will see ... on the new article just published in the ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... The quality of the U.S. diet showed some modest ... of a reduction in the consumption of unhealthy trans ... between the rich and the poor. , , An ... and some cancers. Eating a healthy diet is an ... outcomes. Evaluating population trends in diet quality is important ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... a Global Information System will provide valuable information for ... Institute of Environmental Health Sciences (NIEHS), one of the ... the most up-to-date data to public health and safety ... maps, as well as demographic information for local populations. ...
... Some 12.3 percent of all babies -- 499,008 infants -- ... according to the report released by the National Center for ... 480,000 babies) in 2002 -- and an increase of more ... in 1981. The prematurity rate was 9.4 in 1981; it ...
... the world's vaccine manufacturers will be in a race ... a new technique to more efficiently produce the disarmed ... vaccine in large quantities, life-saving inoculations may be available ... as governments worldwide prepare for a predicted pandemic of ...
Cached Biology News:NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina 2UW scientists report a new method to speed bird flu vaccine production 2UW scientists report a new method to speed bird flu vaccine production 3
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
Biology Products: